Get the Stockscreener App
11.43
3.53%
0.39
Pre-market:
11.27
-0.16
-1.40%
Corbus Pharmaceuticals Holdings Inc stock is traded at $11.43, with a volume of 262.56K.
It is up +3.53% in the last 24 hours and up +16.63% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$11.04
Open:
$11.25
24h Volume:
262.56K
Relative Volume:
1.10
Market Cap:
$202.73M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.912
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
+7.12%
1M Performance:
+16.63%
6M Performance:
+2.14%
1Y Performance:
+59.64%
1-Day Range:
$10.97
$11.64
1-Week Range:
$10.28
$11.64
52-Week Range:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
11.43 | 195.81M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.11, Implies 272% Upside - TradingView
Corbus Pharmaceuticals (CRBP) Advances Oncology and Obesity Prog - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Jefferies cuts Corbus Pharmaceuticals stock price target on HNSCC data By Investing.com - Investing.com Canada
[10-Q] Corbus Pharmaceuticals Holdings, Inc. Quarterly Earnings Report - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.44, Implies 275% Upside - TradingView
Corbus Pharmaceuticals Reports Q1 2026 Results: Advances in CRB-701 for Cancer and CRB-913 for Obesity, FDA Alignment, and Upcoming ASCO Data - Minichart
Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update - Traders Union
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook - TipRanks
Corbus Pharmaceuticals Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Corbus Pharmaceuticals 1Q Loss/Shr $1.23 >CRBP - Moomoo
Corbus (NASDAQ: CRBP) details Q1 loss, FDA alignment and obesity trial - Stock Titan
Corbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 Programs - Quiver Quantitative
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Obesity and cancer drug trials hit key 2026 milestones at Corbus - Stock Titan
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals in Norwood - Boston Real Estate Times
Avoiding Lag: Real-Time Signals in (CRBP) Movement - Stock Traders Daily
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals at 500 River Ridge Drive in Norwood - Colliers
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting - Traders Union
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel - Stock Titan
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MSN Money - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim - MarketBeat
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Guggenheim initiates coverage of Corbus Pharmaceuticals Holdings (CRBP) with buy recommendation - MSN
Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN
CRBP Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
Guggenheim Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $45 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus offers upside despite post-FDA update, analyst highlights competitive edge - MSN
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Corporate presentation Summary - Quartr
Corbus Pharmaceuticals (CRBP) Q4 2025 earnings summary - Quartr
Corbus Pharmaceuticals (CRBP) Registration Filing Summary - Quartr
Corbus Pharmaceuticals (CRBP) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 - The Manila Times
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):